GlassScriptPhysician profile
Christopher Ofeldt
NPI 1114413416
$3,429.70
in general payments reported to CMS, 2019-2025
21 companies · $119 in 2025
The $119 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120 · 2020: $2,421 · 2022: $237 · 2023: $372 · 2024: $161 · 2025: $119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $652.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $651.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Liberty Surgical INC. | $2,421.27 | 2020 | |
| Smith+Nephew, INC. | $176.05 | 2019-2024 | Grafix Pl, Stravix Pl, Oasis |
| Zimmer Biomet Holdings, INC. | $124.04 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $109.07 | 2019 | |
| Stryker Corporation | $67.40 | 2023 | Biofoam |
| Treace Medical Concepts, INC. | $64.73 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $63.58 | 2024-2025 | Xifaxan, Trulance |
| Paratek Pharmaceuticals, INC. | $56.82 | 2022-2023 | Nuzyra |
| Nevro Corp. | $55.11 | 2023-2024 | Senza |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $48.45 | 2023 | Jublia |
| Medshape, INC. | $36.34 | 2023 | Dynaclip Bone Fixation System, Quattro, 22mm X 20mm X 20mm, Dynanail Mini |
| Antares Pharma, INC. | $33.24 | 2025 | Xyosted |
| Lilly USA, LLC | $29.96 | 2024-2025 | Mounjaro, Zepbound |
| Organogenesis INC. | $24.03 | 2023 | Puraply |
| Dexcom, INC. | $22.92 | 2024 | Dexcom G6 Transmitter |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioventus LLC | $22.77 | 2022 | |
| Averitas Pharma INC. | $17.50 | 2023 | Qutenza |
| Convatec INC. | $16.51 | 2025 | |
| Orpyx Medical Technologies US INC. | $13.54 | 2023 | Orpyx Si |
| Horizon Therapeutics Plc | $13.32 | 2023 | Krystexxa |
| Alfasigma USA, INC. | $13.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Ofeldt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.